- Home
- GENK vs PRTG Comparison
GENK vs PRTG Comparison
Compare GENK & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- PRTG
- Stock Information
- Founded
- GENK 2011
- PRTG 1973
- Country
- GENK United States
- PRTG British Virgin Islands
- Employees
- GENK N/A
- PRTG N/A
- Industry
- GENK Restaurants
- PRTG Oil & Gas Production
- Sector
- GENK Consumer Discretionary
- PRTG Energy
- Exchange
- GENK Nasdaq
- PRTG Nasdaq
- Market Cap
- GENK 20.4M
- PRTG 17.7M
- IPO Year
- GENK 2023
- PRTG N/A
- Fundamental
- Price
- GENK $3.73
- PRTG $5.69
- Analyst Decision
- GENK Strong Buy
- PRTG
- Analyst Count
- GENK 2
- PRTG 0
- Target Price
- GENK $10.00
- PRTG N/A
- AVG Volume (30 Days)
- GENK 105.8K
- PRTG 234.2K
- Earning Date
- GENK 07-30-2025
- PRTG 08-26-2025
- Dividend Yield
- GENK 0.82%
- PRTG N/A
- EPS Growth
- GENK N/A
- PRTG N/A
- EPS
- GENK N/A
- PRTG N/A
- Revenue
- GENK $214,957,000.00
- PRTG N/A
- Revenue This Year
- GENK $16.62
- PRTG N/A
- Revenue Next Year
- GENK $20.40
- PRTG N/A
- P/E Ratio
- GENK N/A
- PRTG N/A
- Revenue Growth
- GENK 14.40
- PRTG N/A
- 52 Week Low
- GENK $3.16
- PRTG $2.10
- 52 Week High
- GENK $10.33
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- GENK 42.84
- PRTG 39.99
- Support Level
- GENK $3.50
- PRTG $5.24
- Resistance Level
- GENK $3.78
- PRTG $6.84
- Average True Range (ATR)
- GENK 0.26
- PRTG 0.76
- MACD
- GENK -0.01
- PRTG -0.09
- Stochastic Oscillator
- GENK 22.64
- PRTG 18.10
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.